Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma.

MLA

Lecat, Catherine S. Y., et al. “Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma.” Frontiers in Oncology, vol. 11, July 2021, pp. 1–10. EBSCOhost, https://doi.org/10.3389/fonc.2021.703233.

APA

Lecat, C. S. Y., Taube, J. B., Wilson, W., Carmichael, J., Parrish, C., Wallis, G., Kyriakou, C., Lee, L., Mahmood, S., Papanikolaou, X., Rabin, N. K., Sive, J., Wechalekar, A. D., Yong, K., Cook, G., & Popat, R. (2021). Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma. Frontiers in Oncology, 11, 1–10. https://doi.org/10.3389/fonc.2021.703233

Chicago

Lecat, Catherine S. Y., Jessica B. Taube, William Wilson, Jonathan Carmichael, Christopher Parrish, Gabriel Wallis, Charalampia Kyriakou, et al. 2021. “Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma.” Frontiers in Oncology 11 (July): 1–10. doi:10.3389/fonc.2021.703233.